Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 3, 2005, Pages 173-176

  McGlasson, David L ^a,c   Kaczor, Daniel A ^b   Krasuski, Richard A ^a   Campbell, Charles L ^a   Kostur, Maria R ^a   Adinaro, Joseph T ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b Diagnostica Stago Inc   (United States)

^c Building 4430 ^*  (United States)

Author keywords

Activated partial thromboplastin time; Anti activated factor X; Anticoagulant; CTAD; Enoxaparin; Low molecular weight heparin; Sodium citrate; Unfractionated heparin

Indexed keywords

ACTIVATED FACTOR X ANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; CITRATE SODIUM; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CHROMOGENIC ASSAY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; IMMUNOASSAY; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VEIN PUNCTURE;

EID: 17444387403     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000164424.90545.6e     Document Type: Article

References (17)

1. Fristsma GA. Evaluation of hemostasis. In: Rodak BF, (editor): Hematology: clinical principles and applications, 2nd edition. Philadelphia, PA: W.B. Saunders Co; 2002, p. 738.
2. Adler BK. Unfractionated heparin and other antithrombin mediated anticoagulants. Clin Lab Sci 2004; 17:113-117.
3. Adcock DM, Krestin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol 1997; 107:105-110.
4. Adcock DM, Kessin DC, Marlar RA. Minimum volume requirements for routine coagulation testing: dependence on citrate concentration. Am J Clin Pathol 1998; 109:595-599.
5. Storbeck M, Johnson M, Hayward CPM. The effect of low molecular weight heparin on LA testing [Abstract]. Thromb Haemost 1995; 73:1271.
6. Castellone D. Coagulation do's and don'ts. Advance 2004; 13:50-53.
7. Jensen R, Fritsma GA. Preanalytical variables in the coagulation laboratory. Advance 2000; 9:90-94.
8. Castellone D. How to deliver quality results in the coagulation laboratory: commonly asked questions. Lab Med 2004; 4:208-213.
9. Triplett D. Laboratory monitoring of heparin therapy. Hemoliance Times 1997; 2:3.
10. Werner M, Gallagher JV, Ballo MS, Karcher DS. Effect of analytic uncertainty of conventional and point-of-care assays of activated partial thromboplastin time on clinical decisions on heparin therapy. Am J Clin Pathol 1994; 102:237-241.
11. Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122:782-798.
12. NCCLS Document H21-A3. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays, 3rd edition. Villanova, PA: National Committee for Clinical Laboratory Standards; 1998.
13. Evans EW, Turner K. Anti-factor Xa testing for monitoring heparin therapy. Clin Hemost Rev 2000; 14:8-9.
14. Canton MM. Introduction to thrombosis and anticoagulant therapy. In: Harmening DM, (editor): Clinical hematology and fundamentals of hemostasis, 3rd edition. Philadelphia, PA: F.A. Davis Co.; 1997, p. 581.
15. Becton-Dickinson. Evaluation of BD Vacutainer™ 2.7 ml glass CTAD (sodium citrate, theophylline, adenosine and dipyridamole) coagulation tube with normal donors, donors on oral anticoagulant therapy and I.V. anticoagulant. Clinical White Paper VS5816. Franklin Lakes, NJ: BD Vacutainer Systems; 2001, pp. 1-6.
16. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119:104-109.
17. Kitchen S, Preston FB. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996; 75:734-739.